Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01639911 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01639911 is a Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 28 participants.
The verdict
NCT01639911, a Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.
Interventions
- DRUG Alisertib
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-08-14 |
| Est. Completion | 2016-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01639911
The ClinicalTrials.gov registry entry for NCT01639911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alisertib is the first listed.
NCT01639911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01639911 about?
NCT01639911 is a clinical study titled "Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors". This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.
What is the current status of trial NCT01639911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2013-08-14. Estimated completion is 2016-07-28.
What interventions are being tested in trial NCT01639911?
The interventions under investigation include: Alisertib (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01639911?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.